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Synthesis, in vitro, and in vivo 
evaluation of novel 
N‑phenylindazolyl diarylureas 
as potential anti‑cancer agents
Lucas N. Solano1, Grady L. Nelson1, Conor T. Ronayne1, Shirisha Jonnalagadda1, 
Sravan K. Jonnalagadda1, Kaija Kottke2, Robert Chitren3, Joseph L. Johnson2,5, 
Manoj K. Pandey4, Subash C. Jonnalagadda3 & Venkatram R. Mereddy1,2,5*
Novel N‑phenylindazole based diarylureas have been designed, synthesized and evaluated as 
potential anticancer agents. In vitro cell viability studies of these derivatives illustrate good potency 
with  IC50 values in the range of 0.4–50 μM in several cancer cell lines including murine metastatic 
breast cancer 4T1, murine glioblastoma GL261, human triple negative breast cancer MDA‑MB‑231, 
human pancreatic cancer MIAPaCa‑2, and human colorectal cancer cell line WiDr. The ester group in 
the lead compound 8i was modified to incorporate amino‑amides to increase solubility and stability 
while retaining biological activity. Further in vitro studies reveal that lead candidates inhibit tube 
length in HUVEC cells. In vivo systemic toxicity studies indicate that these candidate compounds are 
well tolerated in mice without any significant side effects. Anticancer efficacy studies in WiDr tumor 
xenograft and 4T1 tumor syngraft models demonstrate that the lead candidate 11 exhibits significant 
antitumor properties as a single agent in these tumor models.
Nitrogen‐containing heterocycles are pharmacologically important scaffolds and are present in numerous clini-
cally approved  drugs1–3. Nitrogenous heterocycles offer a unique opportunity in drug development as they read-
ily allow for the manipulation of lipophilicity, polarity, and hydrogen  bonding1–3. These manipulations could 
potentially result in improved physiochemical properties including pharmacokinetics, pharmacodynamics, and 
toxicological profile to enhance efficacy of  drugs1–3. Indazoles are a class of nitrogen-containing heterocycles 
related to the naturally found indoles, are comprised of a benzene fused to a pyrazole and can exist as 1H‐inda-
zole, 2H‐indazole, and 3H‐indazole. Indazoles have been extensively studied for their pharmaceutical properties 
and have been shown to have high compatibility for drug  development4–6. Literature reports indicate that the 
indazole structural unit is utilized in numerous pharmacologically active agents including drugs with anti-cancer 
 properties4–6. For example, indazole-based pazopanib and axitinib have been developed as multi-tyrosine kinase 
inhibitors that are clinically indicated for the treatment of a variety of  cancers7–16.
Ureas are carbonyl groups flanked by two nitrogens which have unique hydrogen bonding capabilities and as 
a result, they are frequently included in the drug design and discovery  process17. Diaryl ureas have recently been 
explored as pharmacophores for the development of anticancer agents with numerous mechanisms of action, 
including anti-angiogenesis17. Examples of diaryl urea containing anticancer agents include regorafenib and 
sorafenib with clinical indications for colorectal and kidney cancers,  respectively18–23.
Owing to the importance of indazoles and diaryl ureas in drug development, we envisioned that conjugat-
ing indazole template with diphenyl urea would provide an opportunity to design novel drug candidates with 
angiogenesis inhibition properties (Fig. 1). In the current work, we have synthesized and evaluated a series of 
N-phenylindazolyl diarylureas derivatives as potential anticancer agents. 
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Results
Synthesis of N-phenylindazolyl diarylureas was initiated by utilizing commercially available starting mate-
rial methyl 1H-indazole-3-carboxylate 1, which was first treated with 4-fluoronitrobenzene 2. The reaction 
underwent substitution under basic conditions to provide the corresponding methyl 1-(4-nitrophenyl)-1H-in-
dazole-3-carboxylate 3. The nitro group in 3 was reduced in the presence of Pd/C and ammonium formate to 
the corresponding amine 4 (Fig. 2A). Separately, p-aminobenzoic acid 5 was reacted with various isocyanates 
6a–k to obtain the corresponding 4-(3-phenylureido)benzoic acids 7a–k (Fig. 2B). Condensation of amine 4 
under peptide coupling conditions with diphenylurea benzoic acids 7a–k provided the corresponding indazole 
Figure 1.  Structural design of N-phenylindazolyl diarylureas as potential anticancer agents.
Figure 2.  (A) Synthesis of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate for use in coupling with 
synthesized (B) para-ureido carboxylic acids 7a–7k. (C) Synthesis of N-phenylindazole diarylureas 8a–k.
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diphenylureas 8a–k (Fig. 2C). Detailed synthetic protocols and spectral characterization can be found in the 
supplemental information.
N-phenylindazole diarylureas 8a–k were then evaluated for their effects on cell viability utilizing 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on aggressive and difficult to treat 
cancer cell lines including murine metastatic breast cancer 4T1, murine glioma GL261-luc2, human triple nega-
tive breast cancer MDA-MB-231, human pancreatic cancer MIAPaCa-2, and human colorectal adenocarcinoma 
WiDr. These cell lines are all derived from aggressive solid tumors, wherein angiogenesis may play an important 
role in both tumor growth and metastasis. Hence, these cell lines offer an appropriate platform to screen candi-
dates containing anti-angiogenesis pharmacophores, including diarylurea template found in 8a–k. Further, these 
cell lines represent both human and murine neoplasms; suitable for in vivo models in both clinically relevant 
xenograft and syngraft based anticancer efficacy studies. These studies indicated that compounds 8a–k showed 
effects on cell viability in various cancer cell lines with  IC50 values in the range of 0.7–50 µM concentration 
(Table 1). However, due to their poor solubility, we hydrolyzed the ester of one of the lead compounds 8i into the 
corresponding carboxylic acid 9 (Fig. 3). Compound 8i was chosen based on its superior effects on cell viability, 
and presence of metabolically stable 4-Cl, 3-CF3 phenylurea  template18–23. However, the acid derivative 9 did 
Table 1.  MTT  IC50 (µM) values of compounds 8a–k and 9–11 in 4T1, GL261-luc2, MDA-MB-231 
MIAPaCa-2, and WiDr cell lines. Average ± SEM of a minimum three separate experiments.
Compound 4T1 GL261-luc2 MDA-MB-231 MIAPaCa-2 WiDr
8a 1.3 ± 0.4 1.9 ± 0.4 4.8 ± 2.9 14.3 ± 6.8 0.7 ± 0.3
8b 1.5 ± 0.3 1.5 ± 0.4 1.6 ± 0.2 20.7 ± 3.1 2.2 ± 0.8
8c 0.9 ± 0.3 1.4 ± 0.1 1.1 ± 0.2 11.1 ± 5.2 6.7 ± 0.1
8d 2.3 ± 0.5 3.9 ± 0.5 2.5 ± 0.5 4.7 ± 0.9 5.4 ± 1.1
8e > 50 > 50 > 50 > 50 > 50
8f 3.0 ± 1.0 3.2 ± 1.2 4.6 ± 1.0 5.6 ± 0.6 2.0 ± 0.7
8g 1.9 ± 0.5 1.8 ± 0.1 5.7 ± 0.8 4.5 ± 0.5 2.7 ± 0.5
8h 1.5 ± 0.2 1.8 ± 0.4 2.4 ± 0.3 6.1 ± 0.4 4.0 ± 1.4
8i 4.6 ± 2.1 1.8 ± 0.4 1.7 ± 0.8 4.1 ± 1.4 3.7 ± 1.8
8j > 50 > 50 > 50 > 50 > 50
8k 6.1 ± 0.3 4.3 ± 0.5 31.0 ± 6.5 5.6 ± 0.5 0.7 ± 0.1
9  > 50  > 50  > 50  > 50  > 50
10 3.9 ± 0.2 1.5 ± 0.4 1.7 ± 0.5 3.8 ± 0.8 1.4 ± 0.1
11 6.8 ± 0.6 1.4 ± 0.9 1.7 ± 0.8 9.2 ± 1.9 7.9 ± 0.3
Figure 3.  Hydrolysis of 8i to generate acid 9 and corresponding amido-amines 10 and 11 with increased 
solubility and potential for enhanced stability.
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not affect cell viability up to 50 µM concentration (Table 1), and we attributed the lack of biological activity to 
decreased cell membrane permeability of more polar carboxylate group. Further, we envisioned that the lipophilic 
methyl ester in 8i, although biologically active in vitro, would be metabolically vulnerable to hydrolysis via plasma 
esterase activity in in vivo systems, and could result in pharmacologically inactive carboxylic acid 9. In this 
regard, we sought to modify the ester group in 8i by introducing stable and solubility-enhancing secondary and 
tertiary amido-amine units with retained lipophilic characteristics. We hydrolyzed 8i and coupled the resulting 
carboxylic acid 9 with N,N-dimethylethane-1,2-diamine and 1-methyl piperazine to obtain the corresponding 
amido-amine derivatives 10 and 11, respectively (Fig. 3). Gratifyingly, compounds 10 and 11 retained similar 
biological activity with regard to cell viability when compared to parent compound 8i (Table 1, Fig. 4).  
Based on their superior biological activity, we selected parent compound 8i and metabolically stable analog 11 
as lead candidates for preliminary in vitro mechanism of action studies. Amino-amide analog 10 also exhibited 
similar potency in vitro, but unhindered secondary amide may limit the translational potential when compared 
to the sterically hindered and stable tertiary amide of 11 with regards to esterase/amidase hydrolysis under 
physiological conditions. Hence, 10 was not subjected for further mechanism studies. Based on the track record 
of 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-phenylurea template in providing anti-angiogenesis  properties21,22, 
the lead candidates were screened for their ability to inhibit tube length in human umbilical vein endothelial cell 
line HUVEC. Tube forming ability of endothelial cell lines is a widely utilized method to evaluate  angiogenesis24 
and hence, compounds 8i and 11 were screened for their ability to inhibit the tube formation of HUVEC in vitro. 
We treated HUVEC cells with increasing doses of 8i and 11, once initiation of tube formation took place. Total 
tube lengths were measured using Image J software and inhibitory response of compounds was estimated. These 
experiments indicated that candidate compound 8i (5 µM) and more potently compound 11 (1 and 5 µM) 
inhibited HUVEC tube length in HUVEC cell lines (Fig. 5). Interestingly, at this concentration both compounds 
were not toxic to HUVEC cells  (IC50 > 25 µM, 12 h; data not shown). Furthermore, we investigated the cytotoxic 
response of compound 8i and 11 on HUVEC cells for 24 h, we noted similar response  (IC50 > 25 µM, 24 h; data 
not shown). Thus, these compounds exhibited inhibitory properties at sub-toxic doses, suggesting the effects on 
tube length were not due to the cytotoxic response of these compounds.
To understand the translational potential and general tolerance of these candidate compounds, in vivo sys-
temic toxicity and efficacy studies were performed. For these studies, compounds 8i, 10, and 11 were chosen 
based on their superior in vitro potency in the experiments described above. Further, these compounds were 
also chosen to evaluate potential effects on in vivo efficacy of varying esterase/amidase vulnerabilities of ester 
(8i), secondary amide (10), and tertiary amide (11). Compounds 8i, 10, and 11 were administered once daily, 
intraperitoneally (i.p.) at a dosage of 25 mg/Kg for 17 days. Body weights, along with behavior, activity, and 
grooming patterns, were measured and observed every day initially, and later at ~ 2–5 days. At the end of the 
study mice in treatment groups showed no significant body weight loss and exhibited normal behavior, activity, 
Figure 4.  Graphical representation of in vitro cell viability assay dose–response curves of lead candidate 
compounds 8i, 10, and 11 in (A) 4T1, (B) GL261-luc2, (C) MDA-MB-231, (D) MIAPaCa-2, and (E) WiDr cell 
lines. (F) Note retained biological activity between parent ester compound 8i and amido derivatives 10 and 
11. Error bars in (A–E) represent the SEM of six technical replicates across three independent experiments, 
with each concentration tested in duplicate for each experiment (n = 6). Error bars in (F)represent the SEM of 
the  IC50 obtained from the three independent experiments (n = 3), and are derived from values in Table 1. All 
compounds were tested at the same concentration range (50–0.39 µM) for relative comparison.
5
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17969  | https://doi.org/10.1038/s41598-020-74572-1
www.nature.com/scientificreports/
and grooming patterns when compared to the control group (Fig. 6). Based on these studies, we deduced that 
the candidate compounds are in general well tolerated. However, organ function tests such as liver and kidney, 
along with necropsy studies of organ harvest and immunohistochemical analysis of microscopic changes need 
to be carried out to fully understand the systemic toxicity of these compounds.
As the lead compounds 8i, 10, and 11 were well tolerated in mice, we next evaluated these compounds for 
anticancer efficacy on a colorectal cancer WiDr xenograft model. Colorectal cancer is the third most prevalent 
malignancy in terms of new cases and deaths in both men and women and hence, we sought to investigate the 
efficacy of candidate compounds in this tumor model. Athymic nude mice were injected with 5 × 106 WiDr 
cells (suspended in 1:1 mixture of PBS-matrigel) subcutaneously on right flank. Tumors were measured every 
2–3 days and treatment was initiated after tumors reached a mean volume of ~ 150 mm3. At this stage, mice 
were randomly assigned into groups (n = 6 mice per group) and mice in groups 1–3 were treated with 8i, 10, and 
11, respectively, at a dosage of 25 mg/kg, i.p, once daily, for 14 days. Group 4 was administered with clinically 
utilized colorectal cancer drug oxaliplatin at a dosage of 10 mg/kg, i.p. once daily and group 5 was injected with 
vehicle (10% DMSO, 10% PEG, 40% HS-15 (18.8% w/v in  H2O), and 40%  H2O). Tumor volume was recorded 
Figure 5.  Compounds 8i and 11 decrease HUVEC tube length in vitro. In vitro tube forming assay, and 
quantification of tube length was performed as described under “Materials and methods”. Briefly, HUVEC cells 
were seeded on top of matrigel and incubated for 4 h to form tubes following VEGF stimulation. Cells were then 
treated with 1 µM and 5 µM of compound 8i and 11 for 12 h. The fold changes were calculated by comparing 
the tube length of treated versus non-treated cells. Statistical significance (Kruskal–Wallis one-way ANOVA) of 
tube length inhibition by compound 8i and 11 was compared to the non-treated cells. All images were captured 
using the same magnification and are representative of 10 fields of view (see scale bar, 250 µm). Bars indicate 
Mean + SD of 30 independent tube length measurements (n = 30, ****P < 0.0001).
Figure 6.  Systemic toxicity study in CD-1 mice. Mean body weight changes ± SEM (n = 6) in mice with the once 
daily intraperitoneal treatment of compounds 8i, 10, and 11.
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every 2–3 days, and starting on day-12, compound 11 showed statistically significant reduction of tumor with 
(P < 0.05) compared to control group (Fig. 7A). Based on the tumor volume, compound 11 exhibited 47% and 
39% tumor growth inhibition compared to control and oxaliplatin treatment groups, respectively. At the end 
of the study, mice were euthanized, and the tumors were resected and weighed. In this case also, compound 11 
showed significant reduction of tumor (P < 0.05) compared to the control group, which accounted for 43% and 
38% of tumor growth inhibition compared control and oxaliplatin treatment groups, respectively (Fig. 7B). In 
support of our working hypothesis regarding the in vivo lability of methyl ester, we did not see any significant 
reduction of tumors with compounds 8i. The N,N-dimethyl ethylene amide 10 exhibited slightly enhanced tumor 
growth inhibition properties, but lack of statistical significant efficacy may be attributed to insufficient metabolic 
stability of secondary amide when compared to the tertiary piperazine amide 11. Additionally, for the duration of 
the experiment, body weight changes were observed in a similar fashion to that of systemic toxicity study (Fig. 6) 
to assess general tolerability of candidate compounds in tumor bearing mice. We observed normal body weight 
gains indicating that compounds were well tolerated in a treatment setting (data not shown).
To further explore the potential of its use as an anticancer agent, we evaluated the tumor growth inhibition 
effects of compound 11 in a highly aggressive stage IV breast cancer 4T1 mouse tumor model that recapitulates 
human cancers and can be studied in a non-genetically modified syngraft setting. 5 × 104 4T1 cells (suspended 
in 1:1 mixture of PBS-matrigel) were inoculated subcutaneously into the right flank of female BALB/c mice, 
and treatment was initiated the following day. Mice were then randomly grouped based on body weight. Group 
1 was treated with 11 (25 mg/kg, i.p., once daily), group 2 was administered with clinically used breast cancer 
drug doxorubicin (0.5 mg/kg, i.p., three times a week) and group 3 was administered vehicle (10% DMSO, 10% 
PEG, 40% HS-15 (18.8%w/v in  H2O), and 40%  H2O). The treatment was continued for 17 days and at the end of 
the study, tumors were resected and weighed where it was found that compound 11 exhibited significant tumor 
growth reduction (48%) compared to the control group and doxorubicin (Fig. 8). In a parallel fashion, treatment 
tolerability was observed similar to systemic toxicity study where candidate compounds were again well-tolerated 
as evidenced by body weight gains, activity, and grooming patterns. Further, it is notable that during optimiza-
tion of the presented 4T1 tumor model, we had administered doxorubicin at higher concentrations (2–4 mg/kg) 
which resulted in intolerable levels of tumor ulcerations; disqualifying higher dosing strategies to be performed 
in the present 4T1 syngraft study. In fact, extensive internalization of tumors along with substantial ulcerations 
in the study limited tumor volume measurements and for that reason, end-point tumor masses were used as the 
reporter of treatment efficacy (Fig. 8).
Discussion
The tumor microenvironment is highly hetereogenous, comprised of numerous tissue types including epithelial 
cancer cells, stromal cells, immune cells and endothelial cells. Endothelial cells, in particular, play a vital role in 
angiogenesis for the supply of nutrients and oxygen throughout the rapidly dividing  tumor25. Hence, numerous 
attempts have been made to develop angiogenesis inhibitors—with effective agents targeting various endothelial 
growth factors and  receptors26. In this regard, we have designed and synthesized a novel class of N-phenylindazole 
containing diarylureas as potential antiangiogenic anticancer agents (Figs. 2, 3). Due to the structural similarity of 
our candidate compounds with other diphenylurea containing clinical angiogenesis inhibitors such as sorafenib 
and regorafenib, we explored the potential of candidate compounds 8i and 11 to inhibit the tube forming ability 
Figure 7.  Tumor growth inhibition properties of lead compounds 8i, 10, and 11 in WiDr tumor xenograft 
model. Data represents the mean + SEM (n = 6) of (A) tumor volumes per day of treatment and (B) end-point 
tumor weights. Two-factor anova statistical analysis was utilized to compare tumor growth between treated 
groups, vehicle control, and positive control group oxaliplatin (*P < 0.05).
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of endothelial cells in a widely employed in vitro model of HUVEC cells. The tube formation assay is a widely 
used model to study  angiogenesis24. This assay evaluates the capability of endothelial cells to divide and migrate in 
response to angiogenic signals, and test compounds can be assessed for their inhibitory effects on these processes. 
Specifically, the in vitro HUVEC model employs angiogenic vascular endothelial growth factor (VEGF) to induce 
and differentiate endothelial cells to form tube-like structures on a supporting matrix. Hence, alterations in the 
tube forming ability of these cells may indicate dysfunction in VEGF stimulatory pathways. Here, we illustrated 
that the lead candidate compounds reduced the tube length of HUVEC cells at non-toxic concentrations and 
hence, may be working through inhibition of angiogenesis and related processes (Fig. 5). Nonetheless, additional 
in vitro and in vivo experiments are needed to fully evaluate the molecular mechanisms of the candidate com-
pounds. Furthermore, the tube length effects of candidate compounds in HUVEC cells may be independent of the 
mechanism of cancer cell death in vitro (Table 1) as serum and nutrient rich mono-cultures are not dependent on 
endothelial cell growth or VEGF stimulated processes for proliferation. Additionally, mechanism of compound 
induced cell death (apoptosis or other means) in in vivo systems where 3D-heterogenous cell types interact to 
promote tumor growth is also likely to be different than either in vitro HUVEC or cancer cell lines. Hence, it is 
likely that the candidate compounds are acting via pleiotropic mechanisms of action to elicit their anticancer 
properties in vitro and in vivo. In fact, diarylurea containing antiangiogenic agents have been found to exhibit 
potency across numerous growth stimulatory  kinases18–23. In particular, numerous mechanisms of cell death have 
been reported for both regorafenib and sorafenib ranging from apoptotsis, necrosis, ferroptosis, autophagy, and 
others; involving numerous reported downstream signaling  pathways27–34. Specifically, it has been reported that 
the diphenyl urea template targets numerous growth stimulatory pathways including RAS-RAF/MEK-ERK along 
with the PI3K-mTOR axis to provide its anticancer  activity35. Additionally, these compounds have been shown 
to target platelet derived growth factors and receptors and epidermal growth factors and receptors; expanding 
on the hypothesized VEGF/R  mechanisms35. Finally, the diphenyl urea template has been utilized in develop-
ing HDAC inhibitors, Aurora kinase inhibitors, and also as DNA-directing alkylating  agents35. Based on these 
reports, we believe that our candidate compounds may also exhibit pleotropic mechanisms of action in inhibit-
ing cell viability in vitro and tumor growth inhibition in vivo with a combination of cytotoxic and static effects 
depending on the tissue type. Nonetheless, in the present study we have designed, synthesized, and evaluated 
a new-class of anticancer agents that exhibit potent effects on cancer cell viability in vitro and have illustrated 
significant tumor growth inhibition activity in two aggressive solid tumor models of colorectal and breast cancer.
Conclusion
In conclusion, we have synthesized novel diphenyl indazole containing diarylurea compounds as potential 
anticancer agents for difficult to treat solid tumors. The synthesized compounds were evaluated against vari-
ous cancer cell lines including murine metastatic breast cancer 4T1, murine glioma GL261-luc2, human triple 
negative breast cancer MDA-MB-231, human pancreatic cancer MIAPaCa-2, and human colorectal adenocar-
cinoma WiDr. Several of the tested candidates inhibited the cell viability in low micromolar concentrations. 
Based on these studies, three candidate compounds 8i, 10, and 11 were selected and further evaluated in vivo 
in colorectal adenocarcinoma WiDr xenograft model. These studies indicated that candidate 11 was superior in 
arresting tumor growth compared to 8i and 10. The lead candidate 11 was also evaluated for its in vivo efficacy 
in aggressive stage IV breast cancer 4T1 syngraft model, where it significantly reduced the tumor growth. Since 
diarylurea based drug candidates are known to exhibit antiangiogenic properties, we further studied candidate 
compounds 8i and 11 for their preliminary in vitro mechanism of action. These studies indicated that candidate 
compounds reduced tube length in endothelial HUVEC cells at sub-toxic concentrations. Further structure 
activity relationship studies are required to synthesize and identify a more potent lead compound that can com-
pletely suppress the tumor growth, wherein detailed mechanism of action studies can be carried out. However, 
Figure 8.  Anticancer efficacy of lead compound 11 and doxorubicin (Dox) in 4T1 tumor syngraft model. Two-
factor anova statistical analysis was utilized to compare tumor growth between treated groups and the vehicle 
control (*P < 0.05).
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the studies described in the manuscript provide a novel indazole diarylurea structural template which can be 
further developed for anticancer applications.
Materials and methods
Cell lines and culture conditions. Human Umbilical Vein Endothelial Cells (HUVEC) were procured 
from ATCC and grown in complete Vascular Cell Basal Medium supplemented with Endothelial Cell Growth 
Kit-VEGF (ATCC). 4T1 cells (ATCC) were grown in RPMI-1640 (corning) supplemented with 10% fetal bovine 
serum (FBS) and penicillin–streptomycin (50 U/ml, 50 µg/ml). GL261-luc2 cells (Perkin Elmer) were grown in 
DMEM medium (corning) supplemented with FBS (10%), and penicillin–streptomycin (50 U/ml, 50 µg/ml) 
with Geneticin (50 µg/ml) as selection marker. MCF7 cells (ATCC) were grown in α-MEM with FBS (5%), non-
essential amino acids (0.1 mM), insulin (10 µg/mL), sodium pyruvate (1 mM), epidermal growth factor (100 ng/
mL), hydrocortisone (10 µg/mL), HEPES (10 mM), and penicillin–streptomycin (50U/ml, 50 µg/ml). MDA-
MB-231 cells (ATCC) were grown in DMEM medium supplemented with FBS (10%) and penicillin–strepto-
mycin (50 U/ml, 50 µg/ml). MIAPaCa-2 cells (ATCC) were grown in DMEM medium supplemented with FBS 
(10%), horse serum (2.5%) and penicillin–streptomycin (50 U/ml, 50 µg/ml). WiDr cells (ATCC) were cultured 
in MEM media supplemented with FBS (10%) and penicillin–streptomycin (50 U/ml, 50 µg/ml).
MTT based cell viability assay. Cellular viability in the presence of test compounds in 4T1, GL261-luc2, 
MDA-MB-231, MIAPaCa-2, and WiDr cancer cells was determined using MTT (3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide) assay as previously described by  us36. Dose response curves in Fig. 4 were gener-
ated using GraphPad Prism 7.04, and were analyzed by means of non-linear regression using a non-constrained/
non-normalized fit model and were parameterized by the log(concentration inhibitor) against response, where 
the response represented the percent cell survival when compared to untreated cells.  IC50 values were extrapo-
lated from the Prism 7.04 model fit, and represent the concentration of compound resulting in 50% cell survival 
between %survival-maximum and %survival-minimum of the resulting logarithmic fit curve. All compounds 
were tested at the same concentrations (50–0.39 µM), where resulting  IC50 values were compared.
In vitro HUVEC tube‑forming assay. In vitro tube formation assay measures the ability of HUVEC cells 
to form capillary-like structures (called tubes) once plated on extracellular matrix support. The endothelial cells 
attach and generate mechanical forces on the surrounding extracellular support matrix to create tracks or guid-
ance pathways that facilitate cellular migration. The resulting cords of cells will eventually form hollow lumens. 
The experiments were performed exactly described by manufacturer’s protocol. Briefly, first one layer of extra-
cellular matrix was made by adding 50 μL/well of matrigel in 96 well plates. The plate was incubated for 45 min 
at 37 °C. The HUVEC cells (2700 cells/ well) were seeded on top of matrigel and incubated for 4 h to form tubes 
upon stimulation with VEGF supplement. After 4 h the plate was investigated for tube formation. Once tube 
was formed, cells were treated with 1 µM and 5 µM of compound 8i and 11 for 12 h. After incubation, cells were 
stained with Calcein AM, and image was captured. The tube length was measured using Image J software. Briefly, 
the Image J software program was opened, and then the file to measure the tube length was selected. The tube 
length was measured using “draw line” icon. The line was drawn on top of tube, next “analyze” icon was selected, 
and the length of all drawn lines was measured and summed. The data were expressed as the means ± SD of the 
tube length. At least 10 images from each well were captured and analyzed.
Systemic toxicity in CD‑1 mice. CD-1 mice (Charles River) were randomly assigned into groups (n = 6 
mice per group) and mice were administered with compounds 8i, 10 and 11 as indicated in the results section. 
Body weights were recorded every day initially and followed by 2–5 days for the duration of the study. At the end 
of the study, mice were euthanized.
Tumor growth inhibition studies. 5 × 106 WiDr cells were suspended in 100µL (1:1 PBS: Matrigel) 
(Corning, cat. no. 356237) and were injected subcutaneously into the right flank of 4-week-old female athymic 
nude mice (Crl:NU(NCr)-Foxn1nu, Charles River). Tumor volume was calculated by measuring the diameter of 
the long side (a) and the diameter perpendicular (b) where V = ab2/2. Tumors were allowed to grow until a mean 
of ~ 150 mm3 was achieved. Mice were then assigned into groups (n = 6 per group). Tumors were measured every 
two or three days. Groups were assigned as follows: compound 8i (25 mg/kg, ip, qd), compound 10 (25 mg/kg, 
ip, qd), compound 11 (25 mg/kg, ip, qd), oxaliplatin (10 mg/kg, ip, qd), and vehicle (10% DMSO, 10% PEG, 40% 
HS-15 (18.8% w/v in  H2O), and 40%  H2O. Intravenous oxaliplatin was not employed to avoid possible tail necro-
sis in line with our IACUC protocol and as also performed in several literature  reports37–39. Additionally, since 
our lead candidate compounds were administered intraperitoneally, we envisioned to administer oxaliplatin also 
in a similar fashion. The study ended after 14 days or when tumors surpassed acceptable IACUC standards. At 
the completion of the study tumors were resected and weighed.
5 × 104 4T1 cells were suspended in 100 µL (1:1 PBS: Matrigel) and were injected subcutaneously into the 
right flank of 4-week-old female BALB/c (BALB/cAnNCrl, Charles River). The following day, mice were ran-
domly assigned into various groups (n = 8 mice per group) and the treatment was initiated. The compounds were 
administrated once daily, intraperitoneally. Group 1 was treated with compound 11 (25 mg/Kg), group 2 was 
given doxorubicin (0.5 mg/Kg, three times a week)40, and group 3 was designated as control group and injected 
with vehicle. The compounds were solubilized in a mixture of 10% mL DMSO, 10% PEG, 40% HS15 (18.8% 
w/v in sterile water) and 40% sterile water. At the completion of the study tumors were resected and weighed.
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Statistical analysis. Statistical analysis was conducted using GraphPad Prism version 7.04. 2-factor 
ANOVA was used for in vivo studies. Kruskal–Wallis one-way ANOVA statistical tests were utilized in HUVEC 
tube-forming assays. In all cases, a P-value of < 0.05 was considered significant, and replicates are mentioned in 
the text and or legends accompanying the figures.
Ethical approval. The systemic toxicity and anticancer efficacy studies were approved and in compliance 
with the University of Minnesota’s Institutional Animal Care and Use Committee [Systemic toxicity 1611-
34326A (Fig. 6); WiDr xenograft 1612-34444A (Fig. 7), and 4T1 syngraft 1706-34857A (Fig. 8)]. All studies were 
performed in accordance with the relevant guidelines and regulations, and all protocols were approved by the 
University of Minnesota.
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